NCT06378060View on ClinicalTrials.gov

Clinical Study on Modified Allogeneic Hematopoietic Stem Cell Transplantation Regimen for Severe Aplastic Anemia

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

April 1, 2026

Study Completion Date

April 1, 2027

Conditions
Severe Aplastic Anemia
Interventions
DRUG

Modified transplantation system

Conditioning regimen: fludarabine 30mg/m2×5\~6d,cyclophosphamide 50mg/kg×2d, melphalan 100mg/m2×1d aGVHD prophylaxis: PTCY 25mg/kg×2d, ATG 4.5mg/kg total, MMF 15mg/kg +5d\~+35d, Ruxolitinib 5mg bid -1d\~+50d and 2.5mg bid +51d\~+110d, CSA

Trial Locations (1)

650000

RECRUITING

920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Kunming

All Listed Sponsors
lead

Hematology department of the 920th hospital

OTHER